Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good news. Looking forward to the RNS
Dan’s got his wallet out and paid for the EU nxp002 patent now so that’s something
Its an interesting explanation Older, but these transactions are usually exactly matched time/amount wise by the broker after taking their fee. Today's has quite a price/time gap, maybe it was a DIY job? Whatever its not great seeing 0.17 on the bid side regardless of the cause.
We're they bed and isas, or just made to look like them?
Funny how they never show up as a sell and buy
The last few trading days have seen a lot of 'bed and isa ' transactions - indeed most of the large trades were on last three trading days.
Looks like todays 3 x 1,000,000 trades were sells from the non-isa account and with the 2.8m being the buy in the isa account.
Unfortunate it momentarily depressed the price - no doubt the hope by the investor to get a low buy-in price for the isa.
Just my take on it.
0.17p bid
Someone is losing their nerve...wonder if it's a previous cheerleader?
Also bear in mind we are in a new tax year so will pharma R&D budgets be driven by tax relief or Financial year constraints. According to consultants pharma have the firepower this year.
Trans there is no easy answer to timing but you can look at the history all dates relate to RNSs
18/5 formal partnering for 002 commences suggesting the period before discussions were being held but probably more about requirements hence the delivery of the oral test results
18/9 raise to pay for additional data to support partnering process
18/12 partnering process continues for both products
1/3 wording changes to focus on discussions with licensing partners which suggests due diligence is complete
Same wording was reiterated in the Tim email last week with the emphasis this was the priority. Your guess is as good as mine.
"I think an investment now would be pretty safe in terms of downside being reached."
I wonder how many times that has been said since the start of 2020?
Thanks Mars.
And with that analysis do you have any estimates on likely timescales for key SP changing events to happen?
I think an investment now would be pretty safe in terms of downside being reached. What are others thoughts.
My take of current events not that it is anything but guesswork is that the co is talking to AZ but they are not interested in repurposing although there is no good reason not to find better uses for derivatives of existing drugs so are not there for 002. So AZ are there for 004 that means a different licensee for 002. I think they will not retain any royalty income it will be a clean break. Then they will reverse Oxilio into the Nuformix shell.
@Soup Glad you are well and thanks for your thoughts.
Jiving - 'During his Telegram exchange Dan gave no indication he intended to inform shareholders when an application for orphan status was made.' You are quite correct - Dan did not say that.
My three Telegram transcript posts on the 28th Feb were the verbatim comments from Dan ( I still have the screen grabs covering all his comments) and does not include saying when Orphan drug submission applied for.
My 'Newsflow' post on 29th Feb was a listing where I erroneously included the Orphan drug submission in the incorrect section, thereby incorrectly/ inadvertently inferring that Dan had said it. It should have been in the lower section of possible additional newsflow.
Apologies.
Good to see you back Soup & relieved that your absence was not due to illness!
Regarding patent filing RNSs, there is not a consistent pattern. For example the most recent Japanese patent grant for NXP002 (RNS 23.10.23) was filed in August 2019 & that was not RNS'd at the time. During his Telegram exchange Dan gave no indication he intended to inform shareholders when an application for orphan status was made & I for one was not expecting one.
Thanks for the input Soup.
Good morning Peeps, I'm all good just taking a back seat as there isn't much to say at the moment really.
That said, a few things to add following FX post on a few items, which is always worth questioning.
NXP002 EU patent - From what I can tell, the have issued the 'Intention to Grant', this then starts a 4 month period for paying fees, submitting translations, submitting any requested modifications etc.
Since the Intention to Grant was dated 2 Feb, that would place a Grant date at the beginning of June.
I think some of the £160k placing monies will be needed to pay for some of the above.
Orphan Drug Designation submission.
Again I think some of the placing monies will go to this as they will probably have needed a specific report(s) writing to bring together all of their data etc. Whilst the application is free, it is the work required to get your submission spot on that costs the money.
The EU review process is set out on their website, so yes you can submit at any time, it won't be reviewed until its appropriate slot. So, those submitted up to I think 27 March don't start the review process till 22 April, with results in July.
Just to pick up on Jivings point about the company RNS'ing the submission, I would expect to see that, as yes they previously have notified when they submitted patent filings. See NXP004 patent filing RNS.
Reading the EU orphan designation website, they recommend a pre-app meeting at least 2 months prior to submitting. So when they say they want to start immediately, that doesn't necessarily mean submitting immediately.
NXP004 patents
Like FX I don't know why they haven't RNS'd the Japanese patent approval, since they did so with NXP002.
Ongoing process, I personally think its tied in to a sale of the company as a whole, so they are on hold at the moment on that.
New plan and company presentation.
I think they should issue a 'Business Update' rns to outline the above changes, and possibly a new presentation.
But I think they are looking to sell the company as a whole so aren't bothered about drumming up new investor interest. Its binary, a sale will be at a certain price regardless.
Could also be an after market deal which will be reported in the am
Should have been down 5 to 8% today so the up is 13 to 16%
Something has caused this to be blue is it an off market deal mms do not mark stocks up for no reason.
Agreed Chab,
8% rise when the biggest and last trade of the day was for 0.001808p
Absolute nonsense!
That would be on that 12 pence worth at .22 the mm's trying hard :.)
Nonsense marking it up blue today.Means sweet fanny adams
"Are you sure you're looking at NFX?"
Strangely yes when I refer to NFX I was actually looking at NFX. It started at 0.18 was was up to 0.22 early doors, it then dropped back to 0.18.
PS I also meant to say that if the Ctte for the orphan application raises questions does the stock answer take priority ie the company is focusing on licensing discussions and will the orphan answers have to wait.
Soups last post was 13/3, the day before the last RNS from the co. He is not dealing with the licensees is he?
FX I see Olders post was 29th Feb which was only about 7 weeks ago. I read through his other notes at the time, co seemed keen to submit the orphan application at that point with an eta of 90 days so the end of May, that allows for questions from the Ctte. 7 weeks is not a long time for any govt dept so it may just require patience.
The only comment I have, is the stock answer from the co atm gives the impression that the only priority is liscensing discussions which suggests they are fully occupied. If the ctte raises questions on the application that extends the approval from 60 days to 90 days. I don’t think there is any doubt that IPF is a rare disease so it might be a cart and horse issue.
Does anyone else have an explanation for this?
Where is Soup?